

SUPPLEMENTARY MATERIAL 3:

Humoral and cellular responses from cohort 1 (IMRD immunocompromised ISP+) and cohort 2 (IMRD immunocompetent ISP-) according to diagnosis												
	IMRD ISP+ patients (cohort 1) (n=100)				IMRD ISP- patients (cohort 2) (n=47)				p (cohort 1/cohort 2)			
	RA1 n=42	SLE1 n=32	SS1 n=14	SJ1 n=12	RA2 n=13	SLE2 n=12	SS2 n=10	SJ2 n=12				
Disease duration	14.7 (6.5-20)	11.9 (8-16)	10.7 (6-13)	9 (6-15)	13.2 (6-21)	9.17 (7.2-14.5)	10.3 (10-12)	5.5 (1-10)	0.18	0.21	0.25	0.43
Seroconversion	25 (59%)	20 (63%)	7 (50%)	6 (50%)	11 (85%)	9 (75%)	9 (90%)	9 (75%)	0.13	0.59	0.13	0.07
IgG anti-spike mean \pm SD (BAU/mL)	145.8 \pm 24	253.8 \pm 236	526 \pm 319	236 \pm 29	331 \pm 2980	522 \pm 250	754 \pm 270	399.5 \pm 399	0.09	0.07	0.63	0.13
CD4 T-cell responders (n, %)	26 (62%)	17 (53%)	7 (50%)	7 (58%)	11 (85%)	10 (83%)	8 (80%)	8 (66%)	0.17	0.12	0.29	0.29
CD8 T-cell responders (n, %)	26 (62%)	18 (56%)	7 (50%)	5 (42%)	11 (85%)	11 (92%)	8 (80%)	6 (50%)	0.13	0.07	0.29	0.39
Glucocorticoid cumulative dose (mg)	11069 \pm 1059	11712 \pm 14780	3168 \pm 1949	7772 \pm 6840	2839 \pm 1660	1066 \pm 1210	177 \pm 4330	1392 \pm 1860	0.007*	0.004*	0.003*	0.001*
Methotrexate cumulative dose (mg)	6580 \pm 5380	2263 \pm 2520	124 \pm 372	1431 \pm 2050	2745 \pm 2600	0	593 \pm 1450	0	0.006*	0.002*	0.008*	0.02*